Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, following the company’s third-quarter results, posting EPS …
In a research report issued yesterday, Roth Capital analyst Joseph Pantginis maintained a Buy rating on Rexahn Pharmaceuticals (NYSE:RNN) with a $3 price target, …
In a research report released July 18, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Rexahn Pharmaceuticals (RNN) with a $3 price target, …
